CN112512518A - 羟基芫花素在制备抗肿瘤药物中的应用 - Google Patents

羟基芫花素在制备抗肿瘤药物中的应用 Download PDF

Info

Publication number
CN112512518A
CN112512518A CN201880096202.7A CN201880096202A CN112512518A CN 112512518 A CN112512518 A CN 112512518A CN 201880096202 A CN201880096202 A CN 201880096202A CN 112512518 A CN112512518 A CN 112512518A
Authority
CN
China
Prior art keywords
hydroxygenkwanin
nanoparticles
stabilizer
nanoparticle
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880096202.7A
Other languages
English (en)
Other versions
CN112512518B (zh
Inventor
王向涛
李怡静
李好文
敖惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Plant Development of CAMS and PUMC
Original Assignee
Institute of Medicinal Plant Development of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Plant Development of CAMS and PUMC filed Critical Institute of Medicinal Plant Development of CAMS and PUMC
Publication of CN112512518A publication Critical patent/CN112512518A/zh
Application granted granted Critical
Publication of CN112512518B publication Critical patent/CN112512518B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种羟基芫花素纳米粒，包括羟基芫花素和稳定剂，其中所述羟基芫花素与稳定剂的质量比为1:0.02～1：10。本发明还提供了上述羟基芫花素纳米粒的制备方法以及制备抗炎、抗氧化、心脑血管保护、神经保护、免疫调节、抗肿瘤药物中的应用。本发明发现的羟基芫花素纳米粒在人工胃肠液及血浆中能保持稳定不聚沉，既适合口服给药，也适合静脉注射。通过体外细胞毒实验表明，羟基芫花素纳米粒表现出较羟基芫花素DMSO溶液高得多的肿瘤细胞抑制率。羟基芫花素纳米粒可作为基础剂型制备成供口服、注射、吸入和外用的制剂在临床上应用，静脉注射给药后，且比灌胃给药表现出更高抗肿瘤性。羟基芫花素纳米粒具有较好的安全性。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880096202.7A 2018-06-01 2018-06-01 羟基芫花素纳米粒及其制备方法和在抗肿瘤药物中的应用 Active CN112512518B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/089616 WO2019227482A1 (zh) 2018-06-01 2018-06-01 羟基芫花素在制备抗肿瘤药物中的应用

Publications (2)

Publication Number Publication Date
CN112512518A true CN112512518A (zh) 2021-03-16
CN112512518B CN112512518B (zh) 2023-01-10

Family

ID=68697766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880096202.7A Active CN112512518B (zh) 2018-06-01 2018-06-01 羟基芫花素纳米粒及其制备方法和在抗肿瘤药物中的应用

Country Status (2)

Country Link
CN (1) CN112512518B (zh)
WO (1) WO2019227482A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957050A (zh) * 2021-11-24 2022-01-21 李国强 一种nkt细胞的培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103120795A (zh) * 2011-10-27 2013-05-29 四川大学 一种靶向巨噬细胞的制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103120795A (zh) * 2011-10-27 2013-05-29 四川大学 一种靶向巨噬细胞的制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONGMEI YAN等: "Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》 *
孙宇薇等: "木犀草素磷脂复合物的制备及其溶解性能研究", 《哈尔滨商业大学学报( 自然科学版)》 *
王后苗等: "花生及其他植物中木犀草素的研究进展", 《中国油料作物学报》 *

Also Published As

Publication number Publication date
CN112512518B (zh) 2023-01-10
WO2019227482A1 (zh) 2019-12-05

Similar Documents

Publication Publication Date Title
CN102056596B (zh) 纳米颗粒制剂及其用途
Sun et al. Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro
US20190224238A1 (en) Tumor therapeutic drug
CN110198742B (zh) 一种纳米炭-铁复合体系及其组合物、制备方法和用途
CN113264906B (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
CN104548125B (zh) 一种聚乙二醇化紫杉醇纳米晶体的制备及其应用
JP2005035977A (ja) 新規なγ−ブチロラクトン化合物及びその医薬組成物
CN105997943B (zh) 一种人血清白蛋白负载喜树碱类药物的纳米颗粒及其制备方法和应用
CN104042567A (zh) 一种蛇葡萄素纳米胶束及其应用
Fathi Karkan et al. Cisplatin-loaded superparamagnetic nanoparticles modified with PCL-PEG copolymers as a treatment of A549 lung cancer cells
CN103179967A (zh) 抗肿瘤药物组合物
WO2017092230A1 (zh) 双黄酮化合物及其治疗癌症和制备药物的用途
CN112512518B (zh) 羟基芫花素纳米粒及其制备方法和在抗肿瘤药物中的应用
CN103494838B (zh) 一种化疗药物组合物
Abdulbaqi Loading of clarithromycin and paclitaxel on prepared Cds/nio nanoparticles as promising nanocarriers
Ao et al. Sensitive tumor cell line for annonaceous acetogenins and high therapeutic efficacy at a low dose for choriocarcinoma therapy
CN108853056B (zh) 一种叶酸靶向修饰共载盐酸阿霉素和藤黄酸纳米结构脂质载体制剂及其制备方法
CN106389385B (zh) 一种基于环糊精及卵磷脂为载体的番荔素纳米粒及其制备方法和应用
CN1919339B (zh) 含有蛋白的葫芦素纳米制剂及制备方法和用途
CN107913249B (zh) 一种组合物及含有该组合物的纳米胶束与应用
CN107286123B (zh) 一种二苯呋喃类化合物的制备方法与应用
CN105879051A (zh) 一种自组装的核壳结构纳米药物的制备及应用
EP2489351A1 (en) Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof
CN109223769B (zh) 一种对番荔枝内酯类药物具有增效减毒作用的纳米粒及其制备方法和应用
CN108836975B (zh) 野蔷薇苷的新应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant